| Overview |
| bsm-51385m |
| EIF2AK3/PERK Monoclonal Antibody |
| WB, IHC-P |
| Mouse, Rat |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| This EIF2AK3 antibody is generated from a mouse immunized with a recombinant protein conjugated synthetic peptide between 530-850 amino acids from human EIF2AK3. |
| Monoclonal |
| 3C3 |
| IgG1 |
| 0.5ug/ul |
| Purified by Protein G. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 9451 |
| Q9NZJ5 |
| PEK; WRS; PERK; Eukaryotic translation initiation factor 2-alpha kinase 3; PRKR-like endoplasmic reticulum kinase; Pancreatic eIF2-alpha kinase; HsPEK; EIF2AK3 |
| Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2-alpha/EIF2S1) on 'Ser-52' during the unfolded protein response (UPR) and in response to low amino acid availability. Converts phosphorylated eIF-2-alpha/EIF2S1 either in a global protein synthesis inhibitor, leading to a reduced overall utilization of amino acids, or to a translation initiation activator of specific mRNAs, such as the transcriptional activator ATF4, and hence allowing ATF4-mediated reprogramming of amino acid biosynthetic gene expression to alleviate nutrient depletion. Serves as a critical effector of unfolded protein response (UPR)-induced G1 growth arrest due to the loss of cyclin-D1 (CCND1). Involved in control of mitochondrial morphology and function. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |